• 2018-07
  • 2020-07
  • 2020-08
  • br Genetic Associations With Persistent Arm Pain br


    Genetic Associations With Persistent Arm Pain
    medical, surgical, and psychosocial characteristics between patients with and without pain. Pain 154:660-668, 2013
    58. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic KRN7000 pain: An update and effect related to mechanism of drug action. Pain 83:389-400, 1999
    60. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from KRN7000 data. Am J Hum Genet 68:978-989, 2001
    61. Tammimaki A, Mannisto PT: Catechol-O-methyltrans-ferase gene polymorphism and chronic human pain: A sys-tematic review and meta-analysis. Pharmacogenet Genomics 22:673-691, 2012
    62. Tian C, Gregersen PK, Seldin MF: Accounting for ances-
    try: Population substructure and genome-wide association studies. Hum Mol Genet 17:R143-R150, 2008
    64. van Helmond N, Steegers MA, Filippini-de Moor GP, Vissers KC, Wilder-Smith OH: Hyperalgesia and persistent pain after breast cancer surgery: A prospective randomized controlled trial with perioperative COX-2 inhibition. PLoS One 11, 2016:e0166601
    65. Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, Vargas A, Vargas A, Lao-Villadoniga JI, Garcia-Fructuoso F, Ramos-Kuri M, Hernandez F, Springall R, Bojalil R, Vallejo M, Marti-nez-Lavin M: Catechol-O-methyltransferase gene haplo-types in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 9:R110, 2007
    68. Xiang X, Jiang Y, Ni Y, Fan M, Shen F, Wang X, Han J, Cui C: Catechol-O-methyltransferase polymorphisms do not play a significant role in pain perception in male Chinese Han population. Physiol Genomics 44:318-328, 2012
    Associations Between PET Parameters and Expression of 
    Alexey Surov*, Hans Jonas Meyer* and Andreas Wienke†
    Ki-67 in Breast Cancer1,2,3 *Department of Diagnostic and Interventional Radiology,
    †Institute of Medical Epidemiology, Biostatistics, and
    Informatics, Martin-Luther-University Halle-Wittenberg,
    OBJECTIVES: Numerous studies investigated relationships between positron emission tomography and proliferation index Ki-67 in breast cancer (BC) with inconsistent results. The aim of the present analysis was to provide evident data about associations between standardized uptake value (SUV) and expression of Ki-67 in BC. METHODS: MEDLINE library, SCOPUS and EMBASE data bases were screened for relationships between SUV and Ki-67 in BC up to April 2018. Overall, 32 studies with 1802 patients were identified. The following data were extracted from the literature: authors, year of publication, number of patients, and correlation coefficients. Associations between SUV and Ki-67 were analyzed by Spearman's correlation coefficient. RESULTS: Associations between SUVmax derived from 18F-FDG PET and Ki-67 were reported in 25 studies (1624 patients). The pooled correlation coefficient was 0.40, (95% CI = [0.34; 0.46]). Furthermore, 7 studies analyzed associations between SUVmax derived from 18F-fluorthymidin (FLT) PET and Ki-67 (178 patients). The pooled correlation coefficient was 0.54, (95% CI = [0.37; 0.70]). CONCLUSION: SUVmax correlated moderately with expression of Ki-67 and, therefore, cannot be used as a surrogate marker for tumor proliferation. Further studies are needed to evaluate associations between PET parameters and histopathological findings like hormone receptor status in breast cancer.
    Breast cancer (BC) is one of the most frequent malignancies in humans [1]. Imaging methods, especially mammography, ultrasound and magnetic resonance imaging, play a fundamental role in the diagnosis of BC [2]. Nowadays, also positron emission tomography (PET) is increasingly used in BC [3–7]. It has been shown that PET besides detection of distant metastases can also provide additional information about tumor histopathology [5–8]. For example, numerous reports suggested that PET parameters, such as the maximal standardized uptake value (SUVmax), depended on the histologic and biologic characteristics of the breast tumor [5,6]. Invasive tumors classified exhibit higher uptake than lower-grade tumors [5–7]. Furthermore, PET parameters can also predict behavior of BC [8–12]. For instance, Higuchi et al. showed that the prognosis of patients with high SUVmax of primary tumors at baseline is significantly worse than that of patients with low SUVmax in operated BC [9]. In addition, PET can predict patient’s response to 
    Address all correspondence to: Dr. Alexey Surov, Department of Diagnostic and Interventional Radiology, University of Leipzig, Liebigstr. 20, 04103 Leipzig, Germany. E-mail: [email protected]